CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 661 enrolled
Drug / intervention
Xagrotincombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05017493
NCT05017493Phase 2Completed

Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin

Biomad AS·interventional·Posted Aug 24, 2021·Updated Dec 2, 2021

In Brief

A Phase 2 clinical trial evaluating Xagrotin for Covid19. Completed, enrolled 661 participants across 1 site.

Detailed Summary

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesIraq

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 24, 2021
Enrollment StartJul 1, 2020
Primary CompletionDec 7, 2020
Study CompletionFeb 8, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.9 years ago

Interventions

Xagrotincombination

A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care